View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 15, 2015updated 24 Nov 2021 5:38am

AstraZeneca divests US rights of Entocort to Perrigo for $380m

AstraZeneca has completed the sale of the US rights for its gastrointestinal drug Entocort (budesonide) to Perrigo for $380m.

AstraZeneca Headquarters London

AstraZeneca has completed the sale of the US rights for its gastrointestinal drug Entocort (budesonide) to Perrigo for $380m.

Entocort is a gastroenterology medicine indicated to treat patients with mild to moderate Crohn’s disease (CD).

The sale is part of the company’s plan to focus on three main therapy areas as the drug is outside its focus area.

Upon completion of the deal, Perrigo paid AstraZeneca $380m to acquire the rights to sell Entocort capsules and the authorised generic Entocort capsules marketed by Par Pharmaceuticals.

“The deal does not include the transfer of any AstraZeneca employees or plants.”

The deal does not include the transfer of any AstraZeneca employees or plants.

In capsule formulation, Entocort is a first-line therapy indicated for the induction and maintenance of clinical remission of mild to moderate active Crohn’s disease featuring the ileum and/or the ascending colon.

As an enema, Entocort is indicated to induct and maintain clinical remission of distal ulcerative colitis in the rectum, sigmoid colon and descending colon.

In July, the company divested global rights of Entocort outside the US to Tillotts Pharma , part of the Zeria Group for $215m.

The drug is currently approved for use in more than 40 countries to treat CD, as well as ulcerative colitis (UC) in certain markets.

Both CD and UC are types of inflammatory bowel disease (IBD), which is one of the most prevalent gastrointestinal (GI) diseases, affecting more than 2.2 million people in Europe and around five million worldwide.


Image: AstraZeneca headquarters in London, UK. Photo: courtesy of AstraZeneca plc.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology